Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Vertex Advances VX-548 in Acute and Neuropathic Pain
Vertex Advances VX-548 in Acute and Neuropathic Pain
Vertex Advances VX-548 in Acute and Neuropathic Pain
Submitted by
admin
on July 22, 2022 - 10:09am
Source:
Yahoo/Businesswire
News Tags:
Vertex Pharmaceuticals
acute pain
neuropathic pain
FDA
VS-548
clinical trials
Headline:
Vertex Advances VX-548 in Acute and Neuropathic Pain
snippet:
VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 -
Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end -
Breakthrough Therapy Designation granted by FDA -
Do Not Allow Advertisers to Use My Personal information
